## PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE

### **CONVEYING PARTY DATA**

Name	Execution Date
Children's Medical Center Corporation	10/01/1997

### **RECEIVING PARTY DATA**

Name:	National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. Government	
Street Address:	NIH Division of Extramural Inventions and Technology Resources (DEITR)	
Internal Address:	6705 Rockledge Drive, Suite 310, MSC 7980	
City:	Bethesda	
State/Country:	MARYLAND	
Postal Code:	20892-7980	

## PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	08740168

### **CORRESPONDENCE DATA**

Fax Number: (301)480-0272

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Email: edison@nih.gov

Correspondent Name: Director, DEITR

Address Line 1: NIH, 6705 Rockledge Drive, Suite 310

Address Line 2: MSC 7980

Address Line 4: Bethesda, MARYLAND 20892-7980

NAME OF SUBMITTER: Director, DEITR, NIH

Total Attachments: 2

source=08740168-p0001 - p0002#page1.tif source=08740168-p0001 - p0002#page2.tif

PATENT 500537081 REEL: 020935 FRAME: 0456

# EIR# 1504801-97-0003

## LICENSE TO THE UNITED STATES GOVERNMENT

Invention Title:

Endostatin Cell Proliferation Inhibitor and Method of Use

Inventor(s):

Michael O'Reilly, M. Judah Folkman

Patent or Application Serial No.:

08/740,168

U.S. Filing/Issue Date:

10/22/96

Grant/Contract Identification Number:

PO1 CA 45548-11

Foreign Applications filed/intended:

in (countries): Albania, Armenia, Austria, Australia, Azerbaijan, Barbados, Bulgaria, Brazil, Belarus, Canada, Switzerland and Liechtenstein, China, Czech Republic, Germany, Denmark, Estonia, Spain, Finland, united Kingdom, Georgia, Hungary, Iceland, Japan, Kenya, Kyrgyzstan, Democratic People's Republic of Korea, Republic of Korea, Kazakstan, Sri Lanka, Libera Lesotho, Lithuania, Luxembourg, Latvia, Republic of Moldova, Madagascar, the former Yugoslav Republic of Macedonia, Mongolia, malawi, Mexico, Norway, New Zealand, Poland, Portugal, Romania, Russian Federation, Sudan, sweden, Singapore, Slovenia, Slovakia, Tajikistan, Turkmenistan, Turkey, Trinidad and Tobago, Ukraine, Uganda, Uzbekistan, Vietnam in regions: ARIPO (Kenya, Lesotho, Malawy, Sudan, Swaziland, Uganda, and any other state which is a contracting state of the Harare Protocol and of the PCT), Eurasian (Azerbaijan, Belarus, Kazakstan, Russian Federation, Tjikistan, Turkmenistan, and any other State which is a contracting State of the Eurasian Patent Convention and of the PCT), Europe (Austria, Belgium, Switzerland and Lichetenstein, Germany, Denmark, Spain, France, United Kingdom, Greece, Ireland, Italy, Luxembourg, Monaco, Ntherlands, Portugal, Sweden and any other state which is a Contracting State of the European Patent Convention and of the PCT), OAPI (Burkina Faso, Benin, Central African Republic, Congo, Cote D'Ivoire, Cameroon, Gabon, Guinea, Mali, Mauritania, Niger, Senegal, Chag, Togo and any other state which is a member State of OAPI and a Contracting State of the PCT)

The invention identified above is a Subject Invention under 35 U.S.C. 200, et seq., and the Standard Patent Rights clause at 37 CFR 401.14 or FAR 52.227-11, which are included among the terms of the above-identified grant/contract award from the Public Health Service/National Institutes of Health. This document is confirmatory of:

- 1. The nonexclusive, nontransferable, irrevocable, paid-up license granted to the Federal Government in the invention described in the patent application and in any and all divisions, continuations, and continuations in part, and in any and all patents and re-issues granted thereon; and
- 2. All other rights acquired by the Government by reason of the above identified grant/contract award and the laws and regulations which are applicable to the award.

The Government is hereby granted an irrevocable power to inspect and make copies of the above-identified patent application.

Signed this 1 day of October, 1997.

William New, Vice President Research Administration

For:

Children's Hospital Medical Center Corporation

At:

300 Longwood Avenue, Boston, MA 02115